Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ibandronate in benign bone disease.

Tania Winzenberg1, Graeme Jones

  • 1Menzies Research Institute, Level 2/199 Macquarie St, Hobart TAS Australia 7000, Australia. tania.winzenberg@utas.edu.au

Reviews on Recent Clinical Trials
|May 14, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serological evidence linking viral infections to incident risk of hip and knee osteoarthritis.

Bone & joint research·2026
Same author

Implementing good life with OsteoArthritis from Denmark (GLA:D®) in public outpatient settings in Tasmania, Australia.

Osteoarthritis and cartilage open·2026
Same author

Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Cost-effectiveness of yoga vs. strengthening exercise for treating knee OA: Evidence from a randomized controlled trial.

Osteoarthritis and cartilage·2026
Same author

Multisite chronic pain and incident multiple sclerosis: A prospective cohort study.

Brain, behavior, and immunity·2026
Same author

Correction: A meta-analysis of previous falls and subsequent fracture risk in cohort studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Guar Gum, Partially Hydrolyzed Guar Gum, and Human Gut Health: A Narrative Review.

Reviews on recent clinical trials·2026
Same journal

The Gut Microbiota: A Functional Hub Linking Nutrition, Immunity, and Cardiovascular Health.

Reviews on recent clinical trials·2026
Same journal

Rupture of Renal Pelvis: A Case Report and Literature Review of a Rare Complication of Ureteral Lithiasis.

Reviews on recent clinical trials·2026
Same journal

Comparison between Tightrope and Hook Plate Techniques in the Treatment of Acromioclavicular Joint Dislocations: A Systematic Review and Meta-Analysis.

Reviews on recent clinical trials·2026
Same journal

Cerebral Air Embolism after Small-bore Chest Tube Insertion in a Patient with Hydropneumothorax: A Case Report.

Reviews on recent clinical trials·2026
Same journal

Pharmacological Interventions in Primary Amoebic Meningoencephalitis: Clinical Challenges and Strategic Solutions.

Reviews on recent clinical trials·2026
See all related articles

Ibandronate effectively treats postmenopausal osteoporosis and other benign bone diseases. Intermittent oral dosing shows similar efficacy to daily low doses, potentially improving patient adherence and fracture prevention.

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Clinical Trials

Background:

  • Ibandronate is a bisphosphonate used for benign bone diseases, particularly postmenopausal osteoporosis.
  • Its efficacy has been explored in conditions like corticosteroid-induced osteoporosis and Paget's disease.

Purpose of the Study:

  • To review randomized controlled trial evidence on ibandronate's use in benign bone diseases.
  • To discuss dosage regimens, efficacy, and safety for various conditions.

Main Methods:

  • Systematic review of human randomized controlled trials.
  • Analysis of data on postmenopausal osteoporosis, corticosteroid-induced osteoporosis, Paget's disease, and other rare bone conditions.

Main Results:

Related Experiment Videos

  • Intermittent high-dose oral ibandronate demonstrates efficacy comparable to daily low-dose regimens for postmenopausal osteoporosis.
  • A mild increase in adverse events was noted with intermittent dosing.

    • Conclusions:

    • Ibandronate is a viable treatment option for postmenopausal osteoporosis and other benign bone disorders.
    • Extended dosing intervals may enhance patient compliance and fracture prevention, warranting further investigation.